EUCTR2007-002876-32-GB进行中（未招募）1 期
A multicentre, randomised, placebo controlled trial of lactic acid bacteria in the prevention of antibiotic-associated diarrhoea (AAD) and Clostridium difficile diarrhoea (CDD) in patients aged 65 years and over admitted to hospital and receiving antibiotics (06/39/02)
niversity of Wales Swansea0 个研究点目标入组 2,974 人开始时间: 2008年8月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,974
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •People aged =65 years admitted to hospital without diarrhoea and who have been exposed to one or more antibiotics within the last 7 days or are about to start antibiotic treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •People with known immunosuppressive disorder, prosthetic heart valve or active inflammatory bowel disease (the latter defined as requiring specific treatment in the past 12 months)
- •People with a previous history of adverse reactions to probiotics
- •Informed consent not granted by patient or their carer(s)
研究者
相似试验
已完成
不适用
Probiotics in the prevention of antibiotic-associated and C. difficile diarrhoeaISRCTN70017204Swansea University (UK)2,974
尚未招募
不适用
ebulised heparin for lung injuryPatients with or at risk of developing Acute Respiratory Distress Syndrome.Respiratory - Other respiratory disorders / diseasesACTRN12612000418875St.Vincents Hospital/Institute256
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 20.0Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-DEniversité catholique de Louvain (UCL)296
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 20.0Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-PTniversité catholique de Louvain (UCL)296
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 19.1Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-BEniversité catholique de Louvain (UCL)296